Table 2.
Datea | N | Pre-treatment (EPG) |
Post-treatment (EPG) |
FECR (95% CI) | ||
---|---|---|---|---|---|---|
Mean | Range | Mean | Range | |||
Group 4 | ||||||
A | 10 | 1317.0 | 620–1970 | 105.0 | 0–320 | 93.5% (85.6–97.6) |
B | 8 | 131.3 | 10–320 | 118.9 | 0–350 | 33.8% (13.4–61.9) |
C |
15 |
1605.3 |
10–2680 |
4.0 |
0–20 |
99.8% (99.4–99.9) |
Group 5 | ||||||
A | 16 | 968.1 | 550–1720 | 348.8 | 20–1170 | 70.5% (55.5–88.9) |
B | 16 | 348.8 | 20–1170 | 358.1 | 20–760 | 23.5% (12.6–45.0) |
C |
18 |
1278.9 |
210–2460 |
174.1 |
0–670 |
87.7% (79.6–93.1) |
Group 6 | ||||||
A | 19 | 1080.0 | 510–1980 | 332.6 | 20–880 | 74.5% (62.4–83.2) |
C | 25 | 1246.3 | 470–2490 | 570.0 | 10–1490 | 62.0% (48.3–72.4) |
Ivermectin treatments administered on A: February 6, B: February 28, and C: June 8, 2020.